氟铁龙治疗腺癌、胃肠道癌的近期疗效

CLINICAL RESULT OF FURTULON FOR BREAST CANCER AND GASTROINTESTNAL CARCINOMAS

目的:总结氟铁龙(Furtulon简称FTL)治疗乳腺癌和胃肠道癌的疗效及临床经验,探讨其临床应用前景。方法:采用回顾性研究的方法,将应用FTL2个疗程以上的112例上述病种,分成术后辅助化疗组与晚期癌症(包括术后复发、转移)治疗组,并按不同肿瘤分类统计分析。用药方法采用FTL400mgTid×14d,休息14d为一疗程。连续6个疗程后休息3个月,再连续6疗程。乳腺癌加用三苯氧胺(TAM)10mgBid或甲孕酮(MAP)100mgtid或500mgqd;晚期胃肠道癌加用丝裂霉素(MMC)6mg/m2～8mg/m2,iv,dl。结果:随访1a～3a,术后辅助治疗组76例中,复发3例,复发率为3.9%;远处转移7例,转移率为9.2%,其余均健在。晚期癌症治疗组36例中,乳腺癌有效率为62.5%;胃癌、结肠癌和直肠癌的有效率分别为42.8%、37.5%和38.5%,总有效率为44.4%。本组用药4个疗程以上病例与用药4个疗程以下病例,无论是术后的辅助化疗还晚期的姑息治疗,其疗效均相似(P<0.05)。全组除1例发生严重腹泻对症处理外,其余均无明显毒副作用。结论:氟铁龙对胃肠道恶性肿瘤,尤其是乳腺癌有较好的疗效,可以作为乳腺癌,胃肠道癌的术后辅助化疗,也可应用晚期乳腺癌、胃肠道癌的治疗及术后复发转移的再治疗。

Objective:To summarize the efficacy and clinical experience of FTL in breast cancer and gastrointestinal carcinomas,and to search its prospect of clinical usage.Methods:112 patients who had taken FTL for at least two cycles were divided into two groups:One was postoperative adjuvant chemotherapy (Group I)and the orher was the treatment of advanced or recurrent patients (Group II).Statistic analysis is administered according to various sorts of carcinomas.Adninistration of FTL:FTL 0.4 tid×14 days,rest 14 days.Breast cancer Group I:FTL 0.4 tid×14 days,TAM 10 mg bid ,Group II:FTL 0.4 tid×14 days ,MAP 100 mg tid or 500 mg qd.Gastroinrestinal carcinoma Group I:FTL 0.4 tid×14 days ,Group II:FTL 0.4tid×14 days ,MMC(6～8) mg/m 2 iv dl.Results:With following up for one to three years ,in the 76 patients of the postoperative adjuvant chemorherapy group ,the rate of local recurrence was 3.9%(3/76)and the rate of metastasis was 9.2%(7/76).Except the above conditions ,all the patients of this group are alive and free of disease .In the 36 patients of the treated group with advanced or recurrent cancer,the response rate of FTL are 62.5%(5/8)in breast cancer,42.8%(3/7)in gastric cancer ,37.5%(3/8)in colonic cancer,and 44.4%(16/36)in total cases. However, the patients treated by FTL≥4 courses or 2 to 3 courses,the clinical resuots of group I and group II were not different in this series.In all patients ,only one stopped taking FTL because of severe diarrhea,and none of the others had singnificant side effects .Conclusion:FTL has higher respons to breast cancer and gastrointestinal carcinoma .It was suggested that the administration of FTL with TAM for postoperative chemotherapy of breast cancer,and administration of FTL with MAP for advanced or recurrent breast cancer.It was also suggested that the administration of FTL with MMC for postoperative adjuvant chemotherapy of gastrointestinal carcinoma and for treatment of advanced or recurrent gastrointestinal carcinoma .